Scott A Waldman

List of Publications by Year
in descending order

318 papers	10,520 citations	28274 55 h-index	51608 86 g-index
320 all docs	320 docs citations	320 times ranked	9046 citing authors

#	Article	IF	Citations
1	Emerging drug targets for colon cancer: A preclinical assessment. Expert Opinion on Therapeutic Targets, 2022, 26, 207-216.	3.4	4
2	A Î²-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1276-1296.	4.5	6
3	T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C. Frontiers in Immunology, 2022, 13, 855759.	4.8	12
4	Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. American Journal of Gastroenterology, 2022, 117, S21-S26.	0.4	7
5	Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. American Journal of Gastroenterology, 2022, 117, S6-S13.	0.4	9
6	A Î²â€cateninâ€TCFâ€sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. FASEB Journal, 2022, 36, .	0.5	0
7	GUCY2Câ€Enriched Intestinal Neuropod Cells Modulate Visceral Pain. FASEB Journal, 2022, 36, .	0.5	1
8	Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. Npj Vaccines, 2022, 7, .	6.0	5
9	From leptin to lasers: the past and present of mouse models of obesity. Expert Opinion on Drug Discovery, 2021, 16, 777-790.	5.0	0
10	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in Medicine, 2021, 15, 201-217.	1.4	1
11	Stem cells as therapeutic targets in colorectal cancer. Personalized Medicine, 2021, 18, 171-183.	1.5	6
12	Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Alimentary Pharmacology and Therapeutics, 2021, 53, 1250-1267.	3.7	32
13	Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opinion on Therapeutic Targets, 2021, 25, 335-346.	3.4	7
14	The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. Expert Opinion on Biological Therapy, 2021, 21, 1335-1345.	3.1	5
15	Emerging targets for the diagnosis of Parkinsonâ€™s disease: examination of systemic biomarkers. Biomarkers in Medicine, 2021, 15, 597-608.	1.4	0
16	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 117-129.	0.7	6
17	Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biology and Therapy, 2021, 22, 544-553.	3.4	6
18	Cardiopoietic stem cell therapy in ischaemic heart failure: longâ€term clinical outcomes. ESC Heart Failure, 2020, 7, 3345-3354.	3.1	23

#	Article	IF	Citations
19	An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. Expert Review of Clinical Pharmacology, 2020, 13, 1125-1137.	3.1	7
20	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. , 2020, 8, e001046.		16
21	Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biology and Therapy, 2020, 21, 799-805.	3.4	13
22	APC-Î²-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biology and Therapy, 2020, 21, 441-451.	3.4	10
23	Biomarker targeting of colorectal cancer stem cells. Biomarkers in Medicine, 2019, 13, 891-894.	1.4	3
24	NHERF3 is necessary forEscherichia coliheat-stable enterotoxin-induced inhibition of NHE3: differences in signaling in mouse small intestine and Caco-2 cells. American Journal of Physiology - Cell Physiology, 2019, 317, C737-C748.	4.6	8
25	Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. Brain Structure and Function, 2019, 224, 2983-2999.	2.3	19
26	Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. Human Pathology, 2019, 87, 103-114.	2.0	18
27	Therapeutic targeting of gastrointestinal cancer stem cells. Regenerative Medicine, 2019, 14, 331-343.	1.7	9
28	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. , 2019, 7, 104.		43
29	Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation. Clinical and Translational Gastroenterology, 2019, 10, e00016.	2.5	8
30	TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. Journal of Immunology, 2019, 202, 1301-1310.	0.8	6
31	Health Care Evolves From Reactive to Proactive. Clinical Pharmacology and Therapeutics, 2019, 105, 10-13.	4.7	26
32	Guanylate cyclase C (GUCY2C) as a preventative and therapeutic target in colorectal cancers (CRCs) arising through divergent genomic pathways.. Journal of Clinical Oncology, 2019, 37, 595-595.	1.6	0
33	Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunology Research, 2018, 6, 509-516.	3.4	100
34	First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery. JACC: Cardiovascular Interventions, 2018, 11, 412-414.	2.9	6
35	Process Improvement for Maximized Therapeutic Innovation Outcome. Clinical Pharmacology and Therapeutics, 2018, 103, 8-12.	4.7	5
36	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut, 2018, 67, 1543-1552.	12.1	72

#	Article	IF	Citations
37	Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Statistical Methods in Medical Research, 2018, 27, 2581-2595.	1.5	6
38	Prenatal Regeneration in Clinical Practice. Mayo Clinic Proceedings, 2018, 93, 673-675.	3.0	3
39	The Guanylate Cyclase Câ€"cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Frontiers in Oncology, 2018, 8, 299.	2.8	37
40	Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E676-E693.	3.5	19
41	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 2017, 38, ehw543.	2.2	148
42	Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Review of Clinical Pharmacology, 2017, 10, 549-557.	3.1	28
43	Clinical Pharmacology & Therapeutics: Past, Present, and Future. Clinical Pharmacology and Therapeutics, 2017, 101, 300-303.	4.7	3
44	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prevention Research, 2017, 10, 345-354.	1.5	35
45	Managing Innovation to Maximize Value Along the Discoveryâ€Translationâ€Application Continuum. Clinical Pharmacology and Therapeutics, 2017, 101, 8-12.	4.7	7
46	Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+T Cells. Journal of Immunology, 2017, 198, 3507-3514.	0.8	29
47	GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Research, 2017, 77, 5095-5106.	0.9	12
48	Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Annals of Oncology, 2017, 28, 2135-2141.	1.2	92
49	Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics. Clinical Pharmacology and Therapeutics, 2017, 102, 373-377.	4.7	0
50	ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. Toxins, 2017, 9, 279.	3.4	14
51	GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress. Oncotarget, 2017, 8, 102923-102933.	1.8	8
52	Editorial (Thematic Issue: Ferid Murad, at 80: A Legacy of Science, Medicine, and Mentorship). Current Medicinal Chemistry, 2016, 23, 2556-2558.	2.4	2
53	A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. BMC Cancer, 2016, 16, 766.	2.6	6
54	Big Data Transforms Discoveryâ€"Utilization Therapeutics Continuum. Clinical Pharmacology and Therapeutics, 2016, 99, 250-254.	4.7	9

#	Article	IF	Citations
55	Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Human Gene Therapy Methods, 2016, 27, 238-250.	2.1	22
56	Does obesity promote the development of colorectal cancer?. Expert Review of Anticancer Therapy, 2016, 16, 465-467.	2.4	7
57	Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. Nutrition and Diabetes, 2016, 6, e211-e211.	3.2	33
58	Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infection and Immunity, 2016, 84, 3083-3091.	2.2	27
59	Bioinnovation Enterprise: An engine driving breakthrough therapies. Clinical Pharmacology and Therapeutics, 2016, 99, 8-13.	4.7	8
60	GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. OncoImmunology, 2016, 5, e1227897.	4.6	59
61	Association of Inflammation prior to Kidney Transplantation with Post-Transplant Diabetes Mellitus. CardioRenal Medicine, 2016, 6, 289-300.	1.9	7
62	Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer. Molecular Pharmacology, 2016, 90, 199-204.	2.3	14
63	GUCY2C ligand replacement to prevent colorectal cancer. Cancer Biology and Therapy, 2016, 17, 713-718.	3.4	16
64	Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylinâ€“GUCY2C Paracrine Signaling Axis. Cancer Research, 2016, 76, 339-346.	0.9	64
65	Guanylyl cyclase C signaling axis and colon cancer prevention. World Journal of Gastroenterology, 2016, 22, 8070.	3.3	36
66	Targeting guanylate cyclase C in colorectal cancer: Where are we now?. Drugs of the Future, 2016, 41, 0477.	0.1	1
67	A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients. , 2015, 3, .		12
68	CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. Molecular Pharmaceutics, 2015, 12, 2101-2111.	4.6	40
69	Companion diagnostics at the intersection of personalized medicine and healthcare delivery. Biomarkers in Medicine, 2015, 9, 1-3.	1.4	12
70	Clinical Pharmacology & Therapeutics: The Next Five Years. Clinical Pharmacology and Therapeutics, 2015, 97, 2-6.	4.7	3
71	Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation. Pulmonary Pharmacology and Therapeutics, 2015, 30, 22-31.	2.6	0
72	Guanylyl Cyclase C as a Biomarker. Biomarkers in Disease, 2015, , 363-381.	0.1	0

#	Article	IF	Citations
73	Calorieâ€induced ER Stress Silences the Guanylinâ€GUCY2C Paracrine Axis Underlying Colorectal Cancer in Obesity. FASEB Journal, 2015, 29, LB542.	0.5	0
74	A Novel CDX2 Isoform Regulates Alternative Splicing. PLoS ONE, 2014, 9, e104293.	2.5	4
75	Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. Journal of Clinical Medicine, 2014, 3, 763-794.	2.4	10
76	Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2014, 29, 2268-2277.	0.7	43
77	The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2328-2337.	2.5	49
78	Managing the Innovation Supply Chain to Maximize Personalized Medicine. Clinical Pharmacology and Therapeutics, 2014, 95, 113-118.	4.7	8
79	Policies to aid the adoption of personalized medicine. Nature Reviews Drug Discovery, 2014, 13, 159-160.	46.4	9
80	Selective antigenâ€specific CD4⁺ Tâ€cell, but not CD8⁺ Tâ€or Bâ€cell, tolerance corrupts cancer immunotherapy. European Journal of Immunology, 2014, 44, 1956-1966.	2.9	37
81	The orl rat is more responsive to methacholine challenge than wild type. Pulmonary Pharmacology and Therapeutics, 2014, 29, 199-208.	2.6	3
82	Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1188-1195.	0.8	29
83	GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget, 2014, 5, 9460-9471.	1.8	22
84	Guanylyl Cyclase C as Biomarker. , 2014, , 1-16.		0
85	Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhance Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine. Molecular Pharmaceutics, 2013, 10, 2199-2210.	4.6	63
86	GUCY2C: at the intersection of obesity and cancer. Trends in Endocrinology and Metabolism, 2013, 24, 165-173.	7.1	21
87	Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. Circulation, 2013, 128, 2813-2851.	1.6	100
88	Antiobesity Pharmacotherapy: New Drugs and Emerging Targets. Clinical Pharmacology and Therapeutics, 2013, 95, 53-66.	4.7	147
89	Obesity pharmacotherapy: What is next?. Molecular Aspects of Medicine, 2013, 34, 71-83.	6.4	50
90	Reply. Journal of the American College of Cardiology, 2013, 62, 2454-2456.	2.8	17

#	Article	IF	Citations
91	Colorectal cancer stem cells as biomarkers: Where it all starts?. Journal of Surgical Oncology, 2013, 107, 791-793.	1.7	2
92	Systems-Based Discovery Advances Drug Development. Clinical Pharmacology and Therapeutics, 2013, 93, 285-287.	4.7	9
93	Cardiopoietic Stem Cell Therapy in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2329-2338.	2.8	427
94	Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Review of Clinical Pharmacology, 2013, 6, 557-564.	3.1	11
95	Translational medicine individualizes healthcare discovery, development and delivery. Biomarkers in Medicine, 2013, 7, 1-3.	1.4	8
96	New advances in models and strategies for developing anti-obesity drugs. Expert Opinion on Drug Discovery, 2013, 8, 655-671.	5.0	22
97	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in Medicine, 2013, 7, 23-35.	1.4	9
98	Intestinal GUCY2C Prevents TGF-Î² Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer. Cancer Research, 2013, 73, 6654-6666.	0.9	21
99	Guanylyl cyclase C as a biomarker in colorectal cancer. Biomarkers in Medicine, 2013, 7, 159-167.	1.4	14
100	The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney International, 2013, 83, 487-494.	5.2	55
101	Information Hierarchies Optimize Patient-Centered Solutions. Clinical Pharmacology and Therapeutics, 2013, 93, 3-7.	4.7	7
102	Systems Approaches Evolve Clinical Pharmacology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-2.	2.5	5
103	Molecular Insights Provide the Critical Path to Disease Mitigation. Clinical Pharmacology and Therapeutics, 2013, 95, 3-7.	4.7	6
104	Molecular Staging of Node Negative Patients with Colorectal Cancer. Journal of Cancer, 2013, 4, 193-199.	2.5	18
105	Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. Journal of Cancer, 2013, 4, 172-192.	2.5	14
106	Mechanisms of Weight Regain following Weight Loss. ISRN Obesity, 2013, 2013, 1-7.	2.2	74
107	Colorectal cancer immunotherapy. Discovery Medicine, 2013, 15, 301-8.	0.5	52
108	Advances in cancer immunotherapy. Discovery Medicine, 2013, 15, 120-5.	0.5	10

#	Article	IF	Citations
109	GUCY2C molecular staging personalizes colorectal cancer patient management. Biomarkers in Medicine, 2012, 6, 339-348.	1.4	3
110	Clinical Pharmacology & Therapeutics 2011: Year in Review. Clinical Pharmacology and Therapeutics, 2012, 91, 353-357.	4.7	0
111	Advancing Pharmacometrics and Systems Pharmacology. Clinical Pharmacology and Therapeutics, 2012, 92, 535-537.	4.7	8
112	Knowledge Cycle Transforms Therapeutic Innovation. Clinical Pharmacology and Therapeutics, 2012, 91, 3-8.	4.7	14
113	GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity. PLoS ONE, 2012, 7, e31686.	2.5	71
114	Molecular staging individualizing cancer management. Journal of Surgical Oncology, 2012, 105, 468-474.	1.7	18
115	Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of Surgical Oncology, 2012, 106, 24-30.	1.7	9
116	Phosphorylation of vasodilatorâ€stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. International Journal of Cancer, 2012, 130, 2539-2548.	5.1	38
117	Occult tumor burden contributes to racial disparities in stageâ€specific colorectal cancer outcomes. Cancer, 2012, 118, 2532-2540.	4.1	13
118	Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunology, Immunotherapy, 2012, 61, 713-723.	4.2	24
119	The Value Proposition of Molecular Medicine. Clinical and Translational Science, 2012, 5, 108-110.	3.1	8
120	Effect of a novel CDX2 splice variant on tumorigenicity in gastroesophageal junction adenocarcinoma xenografts.. Journal of Clinical Oncology, 2012, 30, e14619-e14619.	1.6	0
121	Cardiovascular Health: The Global Challenge. Clinical Pharmacology and Therapeutics, 2011, 90, 483-485.	4.7	22
122	MicroRNA Signatures as Diagnostic and Therapeutic Targets. Laboratory Medicine Online, 2011, 1, 1.	0.2	0
123	A Conserved Tissue-Specific Homeodomain-Less Isoform of MEIS1 Is Downregulated in Colorectal Cancer. PLoS ONE, 2011, 6, e23665.	2.5	31
124	Contrast-Enhanced Ultrasound Imaging of Sentinel Lymph Nodes After Peritumoral Administration of Sonazoid in a Melanoma Tumor Animal Model. Journal of Ultrasound in Medicine, 2011, 30, 441-453.	1.7	46
125	Clinical Translational Science 2020: Disruptive Innovation Redefines the Discoveryâ€Application Enterprise. Clinical and Translational Science, 2011, 4, 69-71.	3.1	10
126	Bionic Technologies Transforming the Science of Healthcare Delivery. Clinical and Translational Science, 2011, 4, 84-86.	3.1	3

#	Article	IF	Citations
127	Chronic Diseases: The Emerging Pandemic. Clinical and Translational Science, 2011, 4, 225-226.	3.1	115
128	Widening the Path to Personalized Medicine. Clinical and Translational Science, 2011, 4, 392-394.	3.1	8
129	GUCY2C-targeted cancer immunotherapy: past, present and future. Immunologic Research, 2011, 51, 161-169.	2.9	10
130	Clinical Pharmacology as a Foundation for Translational Science. Clinical Pharmacology and Therapeutics, 2011, 90, 10-13.	4.7	13
131	Regulation of appetite to treat obesity. Expert Review of Clinical Pharmacology, 2011, 4, 243-259.	3.1	34
132	Occult Tumor Burden Predicts Disease Recurrence in Lymph Nodeâ€“Negative Colorectal Cancer. Clinical Cancer Research, 2011, 17, 3293-3303.	7.0	28
133	Clinical pharmacology at the core of translational science. Expert Review of Clinical Pharmacology, 2011, 4, 303-305.	3.1	4
134	Patient-centric clinical pharmacology advances the path to personalized medicine. Biomarkers in Medicine, 2011, 5, 697-700.	1.4	11
135	A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. Journal of Clinical Investigation, 2011, 121, 3578-3588.	8.2	130
136	Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics. Toxins, 2010, 2, 2028-2054.	3.4	29
137	Selection of optimal reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics, 2010, 11, 253.	2.6	81
138	Sizing Up Pharmacotherapy for Obesity. Clinical and Translational Science, 2010, 3, 123-125.	3.1	3
139	Clinical and Translational Science: From Benchâ€Bedside to Global Village. Clinical and Translational Science, 2010, 3, 254-257.	3.1	60
140	Chemiluminescence-based detection of gastrointestinal malignancies. Luminescence, 2010, 25, 463-465.	2.9	5
141	Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2010, 87, 652-662.	4.7	41
142	Molecular Therapeutics From Knowledge to Delivery. Clinical Pharmacology and Therapeutics, 2010, 87, 619-623.	4.7	21
143	Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Review of Endocrinology and Metabolism, 2010, 5, 765-783.	2.4	3
144	Corruption of homeostatic mechanisms in the guanylyl cyclase c signaling pathway underlying colorectal tumorigenesis. Cancer Biology and Therapy, 2010, 10, 211-218.	3.4	10

#	Article	IF	Citations
145	Translational medicine: path to personalized and public health. Biomarkers in Medicine, 2010, 4, 787-790.	1.4	20
146	Taking a Lesson From Microbial Diarrheagenesis in the Management of Chronic Constipation. Gastroenterology, 2010, 138, 813-817.	1.3	41
147	Molecular Staging Estimates Occult Tumor Burden in Colorectal Cancer. Advances in Clinical Chemistry, 2010, 52, 19-39.	3.7	4
148	Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. Human Pathology, 2010, 41, 123-128.	2.0	30
149	<scp>Hot Topic</scp>: Molecular Therapy Drives Patientâ€Centric Health Care Paradigms. Clinical and Translational Science, 2010, 3, 170-171.	3.1	12
150	GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics, 2009, 9, 777-785.	3.1	11
151	Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. Biomarkers in Medicine, 2009, 3, 33-45.	1.4	8
152	Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 745.	7.4	102
153	Clinical pharmacology: a paradigm for individualized medicine. Biomarkers in Medicine, 2009, 3, 679-684.	1.4	11
154	Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncology, 2009, 5, 509-522.	2.4	30
155	Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease. Cancer Research, 2009, 69, 3537-3544.	0.9	35
156	Guanylyl Cyclase C Prevents Colon Cancer Metastasis by Regulating Tumor Epithelial Cell Matrix Metalloproteinase-9. Cancer Research, 2009, 69, 3529-3536.	0.9	36
157	Molecular Diagnostics. Clinical and Translational Science, 2009, 2, 6-8.	3.1	4
158	Translational Medicine in the Era of Health Care Reform. Clinical and Translational Science, 2009, 2, 96-97.	3.1	14
159	Applications of MicroRNA in Cancer: Exploring the Advantages of miRNA. Clinical and Translational Science, 2009, 2, 248-249.	3.1	9
160	Bile Acids Initiate Lineageâ€Addicted Gastroesophageal Tumorigenesis by Suppressing the EGF Receptorâ€AKT Axis. Clinical and Translational Science, 2009, 2, 286-293.	3.1	11
161	Experimental Therapeutics: A Paradigm for Personalized Medicine. Clinical and Translational Science, 2009, 2, 436-438.	3.1	12
162	Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology, 2009, 55, 182-188.	2.9	2

#	Article	IF	Citations
163	A study of microRNAs inâ€ƒsilico and inâ€ƒvivo: diagnostic and therapeutic applications in cancer. FEBS Journal, 2009, 276, 2157-2164.	4.7	30
164	Transitioning biomarkers into the clinic. Expert Review of Clinical Pharmacology, 2009, 2, 9-13.	3.1	1
165	GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?. Drug News and Perspectives, 2009, 22, 313.	1.5	22
166	PHARMACOTHERAPEUTIC CONTINUUM: ENGINEERING THE FUTURE OF INDIVIDUALIZED MEDICINE. , 2009, , 3-5.		0
167	The Novel Role of Guanylyl Cyclase C Signaling in Appetite Suppression and Body Weight Regulation. FASEB Journal, 2009, 23, LB365.	0.5	0
168	CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. BIOforum Europe: Trends and Techniques in Life Science Research, 2009, 3, 14-16.	0.0	1
169	STa peptide analogs for probing guanylyl cyclase C. Biopolymers, 2008, 90, 713-723.	2.4	7
170	Therapeutic Targeting: A Crucible for Individualized Medicine. Clinical Pharmacology and Therapeutics, 2008, 83, 651-654.	4.7	32
171	Pharmacoeconomics in the Era of Individualized Medicine. Clinical Pharmacology and Therapeutics, 2008, 84, 179-182.	4.7	14
172	Sex Modulates Intestinal Transformation by the Tumor-Suppressor GCC. Clinical and Translational Science, 2008, 1, 150-150.	3.1	0
173	Clinical and Translational Sciences: At the Intersection of Molecular and Individualized Medicine. Clinical and Translational Science, 2008, 1, 6-8.	3.1	7
174	Sex Modulates Intestinal Transformation by the Tumorâ€Suppressor GCC. Clinical and Translational Science, 2008, 1, 146-150.	3.1	0
175	Colorectal Cancer Is a Paracrine Deficiency Syndrome Amenable to Oral Hormone Replacement Therapy. Clinical and Translational Science, 2008, 1, 163-167.	3.1	21
176	The Roadmap to Personalized Medicine. Clinical and Translational Science, 2008, 1, 93-93.	3.1	6
177	Cytokine Adjuvanation of Therapeutic Antiâ€tumor Immunity Targeted to Cancer Mucosa Antigens. Clinical and Translational Science, 2008, 1, 263-264.	3.1	8
178	Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert Review of Clinical Pharmacology, 2008, 1, 27-37.	3.1	2
179	Bridging the therapeutic continuum of drug development, regulation and use. Expert Review of Clinical Pharmacology, 2008, 1, 1-3.	3.1	0
180	Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis, 2008, 29, 1601-1607.	2.8	25

#	Article	IF	Citations
181	Previstageâ„¢ GCC test for staging patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2008, 8, 571-578.	3.1	8
182	Guanylyl Cyclase Câ€“Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity. Journal of the National Cancer Institute, 2008, 100, 950-961.	6.3	48
183	Derivation and Fluidity of Acutely Induced Dysfunctional CD8+ T Cells. Journal of Immunology, 2008, 180, 5300-5308.	0.8	3
184	MicroRNA Signatures as Diagnostic and Therapeutic Targets. Clinical Chemistry, 2008, 54, 943-944.	3.2	44
185	Therapeutic burden in cancer revealed by molecular staging. Biomarkers in Medicine, 2008, 2, 1-3.	1.4	1
186	Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomarkers in Medicine, 2007, 1, 187-202.	1.4	10
187	Targeted diagnostics and therapeutics for individualized patient management. Biomarkers in Medicine, 2007, 1, 3-8.	1.4	10
188	Translating MicroRNA Discovery Into Clinical Biomarkers in Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 1923.	7.4	55
189	Acquired and innate cardioprotection. Journal of Applied Physiology, 2007, 103, 1436-1437.	2.5	5
190	The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers. Journal of Clinical Pharmacology, 2007, 47, 697-703.	2.0	26
191	Homeostatic Control of the Crypt-Villus Axis by the Bacterial Enterotoxin Receptor Guanylyl Cyclase C Restricts the Proliferating Compartment in Intestine. American Journal of Pathology, 2007, 171, 1847-1858.	3.8	99
192	H-ras Inhibits RhoA/ROCK Leading to a Decrease in the Basal Tone in the Internal Anal Sphincter. Gastroenterology, 2007, 132, 1401-1409.	1.3	8
193	Guanylyl Cyclase C Suppresses Intestinal Tumorigenesis by Restricting Proliferation and Maintaining Genomic Integrity. Gastroenterology, 2007, 133, 599-607.	1.3	124
194	Relative quantification based on logistic models for individual polymerase chain reactions. Statistics in Medicine, 2007, 26, 5596-5611.	1.6	23
195	Clinical pharmacology: the science of therapeutics. Clinical Pharmacology and Therapeutics, 2007, 81, 3-6.	4.7	29
196	Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation. Clinical Pharmacology and Therapeutics, 2007, 81, 153-155.	4.7	52
197	The Merck Manual, 18th Edition. Clinical Pharmacology and Therapeutics, 2007, 81, 790-791.	4.7	5
198	Evolution of Clinical Pharmacology and Therapeutics. Clinical Pharmacology and Therapeutics, 2007, 82, 233-235.	4.7	0

#	Article	IF	Citations
199	The Paracrine Hormone Hypothesis of Colorectal Cancer. Clinical Pharmacology and Therapeutics, 2007, 82, 441-447.	4.7	61
200	Molecular Medicine Hones Therapeutic Arts to Science. Clinical Pharmacology and Therapeutics, 2007, 82, 343-347.	4.7	29
201	Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen. Clinical Pharmacology and Therapeutics, 2007, 82, 734-739.	4.7	28
202	Individualized Medicine and the Imperative of Global Health. Clinical Pharmacology and Therapeutics, 2007, 82, 479-483.	4.7	24
203	Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends in Biotechnology, 2007, 25, 145-152.	9.3	140
204	Where medicine, business, and public policy intersect. Biotechnology Healthcare, 2007, 4, 33-42.	0.2	7
205	Bile Acids Induce Ectopic Expression of Intestinal Guanylyl Cyclase C Through Nuclear Factor-ÎºB and Cdx2 in Human Esophageal Cells. Gastroenterology, 2006, 130, 1191-1206.	1.3	87
206	Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers. Journal of Clinical Pharmacology, 2006, 46, 291-300.	2.0	86
207	Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry, 2006, 348, 198-208.	2.4	18
208	Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncology, 2006, 2, 705-716.	2.4	17
209	A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer. Clinical Cancer Research, 2006, 12, 4545-4552.	7.0	76
210	Tumor Epithelial Cell Matrix Metalloproteinase 9 Is a Target for Antimetastatic Therapy in Colorectal Cancer. Clinical Cancer Research, 2006, 12, 1876-1882.	7.0	60
211	Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. Molecular Cancer Therapeutics, 2006, 5, 1190-1196.	4.1	13
212	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2005, 5, 701-713.	3.1	60
213	The Putative Tumor Suppressor Cdx2 Is Overexpressed by Human Colorectal Adenocarcinomas. Clinical Cancer Research, 2005, 11, 8549-8556.	7.0	74
214	Interruption of Homologous Desensitization in Cyclic Guanosine 3â€²,5â€²-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins. Cancer Research, 2005, 65, 11129-11135.	0.9	33
215	Proliferative Signaling by Store-Operated Calcium Channels Opposes Colon Cancer Cell Cytostasis Induced by Bacterial Enterotoxins. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1013-1022.	2.5	31
216	TUMOR-TARGETING PEPTIDE-PNA-PEPTIDE CHIMERAS FOR IMAGING OVEREXPRESSED ONCOGENE mRNAS. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1085-1091.	1.1	12

#	Article	IF	Citations
217	Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Human Pathology, 2005, 36, 170-179.	2.0	109
218	Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. Antimicrobial Agents and Chemotherapy, 2004, 48, 4306-4314.	3.2	93
219	Reciprocal Regulation and Integration of Signaling by Intracellular Calcium and Cyclic GMP. Vitamins and Hormones, 2004, 69, 69-94.	1.7	1
220	Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 37-42.	7.1	91
221	Markers of Cell Cycle-Mediated Drug Resistance And Prognosis Of Patients Receiving Preoperative Combined Modality Therapy For Rectal Cancer. Annals of Surgical Oncology, 2004, 11, 949-950.	1.5	2
222	Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica, 2004, 34, 379-389.	1.1	23
223	Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers. Clinical Pharmacokinetics, 2004, 43, 121-129.	3.5	18
224	The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers. Journal of Clinical Pharmacology, 2004, 44, 67-72.	2.0	51
225	Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. Journal of Clinical Pharmacology, 2004, 44, 305-313.	2.0	30
226	Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity. Current Opinion in Hematology, 2004, 11, 7-14.	2.5	31
227	The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity. Journal of Clinical Pharmacology, 2004, 44, 1125-1131.	2.0	19
228	First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2003, 111, S835-S842.	2.9	123
229	Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clinical Therapeutics, 2003, 25, 1407-1419.	2.5	83
230	Effect of Mibefradil on CYP3A4 In Vivo. Journal of Clinical Pharmacology, 2003, 43, 1091-1100.	2.0	28
231	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. Journal of Clinical Pharmacology, 2003, 43, 573-585.	2.0	69
232	Pharmacokinetics of Intramuscularly Administered Ertapenem. Antimicrobial Agents and Chemotherapy, 2003, 47, 1732-1735.	3.2	26
233	Functional and Molecular Characterization of Î²-Adrenoceptors in the Internal Anal Sphincter. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 615-624.	2.5	20
234	Bacterial enterotoxins are associated with resistance to colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2695-2699.	7.1	131

#	Article	IF	Citations
235	Pathological staging and therapy of oesophageal and gastric cancer. Expert Opinion on Pharmacotherapy, 2003, 4, 1083-1096.	1.8	4
236	Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. Journal of Clinical Pharmacology, 2003, 43, 983-989.	2.0	15
237	Exposure-Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice. Journal of Clinical Pharmacology, 2003, 43, 831-839.	2.0	127
238	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. Journal of Clinical Pharmacology, 2003, 43, 573-585.	2.0	3
239	Characterization of etoricoxib, a novel, selective COX-2 inhibitor. Journal of Clinical Pharmacology, 2003, 43, 573-85.	2.0	22
240	Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men. Antimicrobial Agents and Chemotherapy, 2002, 46, 739-745.	3.2	239
241	Pharmacokinetics of Ertapenem in Healthy Young Volunteers. Antimicrobial Agents and Chemotherapy, 2002, 46, 3506-3511.	3.2	137
242	Nitric Oxide Activation of Soluble Guanylyl Cyclase Reveals High and Low Affinity Sites That Mediate Allosteric Inhibition by Calciumâ€. Biochemistry, 2002, 41, 3396-3404.	2.5	20
243	A Comparative Molecular Field Analysis (COMFA) of the Structural Determinants of Heat-Stable Enterotoxins Mediating Activation of Guanylyl Cyclase C. Journal of Medicinal Chemistry, 2002, 45, 1731-1734.	6.4	9
244	Does potency predict clinical efficacy? Illustration through an antihistamine model. Annals of Allergy, Asthma and Immunology, 2002, 89, 7-12.	1.0	29
245	Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides. FEBS Journal, 2002, 269, 2186-2193.	0.2	10
246	In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand. Journal of Nuclear Medicine, 2002, 43, 392-9.	5.0	37
247	Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 739-44.	2.5	17
248	Manufacturer??s Drug Interaction and Postmarketing Adverse Event Data. Drug Safety, 2001, 24, 637-643.	3.2	9
249	Nucleotide requirements for CDX2 binding to thecispromoter element mediating intestine-specific expression of guanylyl cyclase C. FEBS Letters, 2001, 507, 128-132.	2.8	17
250	Ectopic Expression of Guanylyl Cyclase C in CD34+Progenitor Cells in Peripheral Blood. Journal of Clinical Oncology, 2001, 19, 3951-3959.	1.6	56
251	Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7846-7851.	7.1	143
252	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth Muscle Relaxation. , 2001, , 805-828.		0

#	Article	IF	Citations
253	Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency. Journal of Clinical Pharmacology, 2000, 40, 745-751.	2.0	5
254	Human cholecystokinin-A receptor is not an oncofetal protein. Digestive Diseases and Sciences, 2000, 45, 538-543.	2.3	7
255	A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells. Digestive Diseases and Sciences, 2000, 45, 298-305.	2.3	5
256	Colorectal cancer staging and adjuvant chemotherapy. Expert Opinion on Pharmacotherapy, 2000, 1, 737-755.	1.8	17
257	Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology, 2000, 119, 89-96.	1.3	73
258	Guanylyl Cyclase C Messenger RNA Is a Biomarker for Recurrent Stage II Colorectal Cancer. Annals of Internal Medicine, 1999, 131, 805.	3.9	96
259	Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical Pharmacology and Therapeutics, 1999, 65, 348-352.	4.7	63
260	The Molecular Therapeutics Section of the American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology and Therapeutics, 1999, 66, 336-337.	4.7	2
261	Regulation of Nitric Oxide-Responsive Recombinant Soluble Guanylyl Cyclase by Calcium. Biochemistry, 1999, 38, 6441-6448.	2.5	37
262	Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea. FASEB Journal, 1999, 13, 913-922.	0.5	24
263	Binding characteristics of Ustilago maydis topoisomerase I to DNA containing secondary structures. FEBS Journal, 1998, 255, 347-355.	0.2	8
264	Use of guanylyl cyclase c for detecting micrometastases in lymph nodes of patients with colon cancer. Diseases of the Colon and Rectum, 1998, 41, 310-315.	1.3	79
265	Paradoxical Hypotension and Bradycardia after Intravenous Arginine Vasopressin. Journal of Clinical Pharmacology, 1998, 38, 283-286.	2.0	6
266	Adverse Drug Reactions: A Review. Drug Information Journal, 1998, 32, 323-338.	0.5	6
267	Effect of Multiple Doses of Rifampin on the [¹⁴C Nâ€methyl] Erythromycin Breath Test in Healthy Male Volunteers. Journal of Clinical Pharmacology, 1998, 38, 492-495.	2.0	32
268	Single-Dose Pharmacokinetics of Indinavir and the Effect of Food. Antimicrobial Agents and Chemotherapy, 1998, 42, 332-338.	3.2	113
269	Interruption of Escherichia coli Heat-stable Enterotoxin-induced Guanylyl Cyclase Signaling and Associated Chloride Current in Human Intestinal Cells by 2-Chloroadenosine. Journal of Biological Chemistry, 1997, 272, 754-758.	3.4	23
270	The Guanylyl Cyclase Family of Natriuretic Peptide Receptors. Vitamins and Hormones, 1997, 57, 123-151.	1.7	30

#	Article	IF	Citations
271	Cytoplasmic Domains Mediate the Ligand-Induced Affinity Shift of Guanylyl Cyclase C. Biochemistry, 1997, 36, 12921-12929.	2.5	30
272	An Intracellular Adenine Nucleotide Binding Site Inhibits Guanylyl Cyclase C by a Guanine Nucleotide-Dependent Mechanismâ€. Biochemistry, 1996, 35, 3213-3221.	2.5	18
273	Hypotensive Mechanisms of Amifostine. Journal of Clinical Pharmacology, 1996, 36, 365-373.	2.0	33
274	Pharmacokinetics and Pharmacodynamics of Tepoxalin after Single Oral Dose Administration to Healthy Volunteers. Journal of Clinical Pharmacology, 1996, 36, 462-468.	2.0	24
275	Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 14827-14832.	7.1	180
276	Escherichia coli heat-stable enterotoxin receptors. Diseases of the Colon and Rectum, 1996, 39, 171-181.	1.3	57
277	Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin. Journal of Clinical Pharmacology, 1995, 35, 1008-1015.	2.0	28
278	Inhibition of Nitric Oxide Biosynthesis Promotes P-selectin Expression in Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2068-2075.	2.4	90
279	Rat Guanylyl Cyclase C Expressed in COS-7 Cells Exhibits Multiple Affinities for Escherichia coli Heat-Stable Enterotoxin. Biochemistry, 1995, 34, 9095-9102.	2.5	17
280	Allosteric regulation by calcium of rabbit polyclonal anti-cyclic GMP antibody. Biochimica Et Biophysica Acta - General Subjects, 1995, 1243, 143-150.	2.4	2
281	Effects of Food on the Bioequivalence of Different Verapamil Sustainedâ€Release Formulations. Journal of Clinical Pharmacology, 1995, 35, 163-169.	2.0	27
282	Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients. Hypertension, 1995, 25, 37-46.	2.7	114
283	Intestinal Kinetics And Dynamics Of Escherichia Coli Heat-Stabile Enterotoxin In Suckling Mice. Journal of Infectious Diseases, 1994, 170, 1498-1507.	4.0	6
284	Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology, 1994, 107, 1653-1661.	1.3	80
285	Regulation of Particulate Guonylate Cyclase by Notriuretic Peptides and Escherichia coli Heat-Stable Enterotoxin. Advances in Pharmacology, 1994, 26, 67-86.	2.0	11
286	Solubilization and characterization of functionally coupled Escherichia coli heat-stable toxin receptors and particulate guanylate cyclase associated with the cytoskeleton compartment of intestinal membranes. International Journal of Biochemistry & Cell Biology, 1993, 25, 557-566.	0.5	18
287	Sensitivity in detecting drug-induced alterations in the PR interval: Comparison of the surface electrocardiogram measured by a cardiologist versus routine automated computer analysis. American Journal of Cardiology, 1993, 72, 834-836.	1.6	8
288	A 56 kDa binding protein for Escherichia coli heat-stable enterotoxin isolated from the cytoskeleton of rat intestinal membranes does not possess guanylate cyclase activity. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1152, 1-8.	2.6	14

#	Article	IF	Citations
289	Affinity purification of functional receptors for Escherichia coli heat-stable enterotoxin from rat intestine. Biochemistry, 1992, 31, 12-16.	2.5	55
290	Identification and characterization of a new family of high-affinity receptors for Escherichia coli heat-stable enterotoxin in rat intestinal membranes. Biochemistry, 1991, 30, 10738-10745.	2.5	46
291	[36] Immunoaffinity purification of soluble guanylyl cyclase. Methods in Enzymology, 1991, 195, 391-396.	1.0	6
292	[37] Copurification of atrial natriuretic peptide receptor and particulate guanylyl cyclase. Methods in Enzymology, 1991, 195, 397-404.	1.0	1
293	[41] Identification of atrial natriuretic peptide receptors in cultured cells. Methods in Enzymology, 1991, 195, 436-446.	1.0	6
294	Adenine nucleotide regulation of particulate guanylate cyclase from rat lung. BBA - Proteins and Proteomics, 1991, 1077, 99-106.	2.1	37
295	Rat intestinal cell atrial natriuretic peptide receptor coupled to guanylate cyclase. Gastroenterology, 1990, 99, 125-131.	1.3	16
296	Regulation of particulate guanylate cyclase by atriopeptins: relation between peptide structure, receptor binding, and enzyme kinetics. BBA - Proteins and Proteomics, 1989, 999, 157-162.	2.1	5
297	Regulation of particulate guanylatecy cylase by Escherichia coli heat-stable enterotoxin: Receptor binding and enzyme kinetics. International Journal of Biochemistry & Cell Biology, 1989, 21, 1211-1215.	0.5	7
298	Atrial natriuretic peptides: Receptors and second messengers. BioEssays, 1989, 10, 16-19.	2.5	27
299	Comparison of particulate guanylate cyclase in cells with and without atrial natriuretic peptide receptor binding activity. Molecular and Cellular Biochemistry, 1989, 90, 19-25.	3.1	3
300	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth-Muscle Relaxation. Developments in Cardiovascular Medicine, 1989, , 825-846.	0.1	7
301	Atrial Natriuretic Peptide, Oxytocin, and Vasopressin Increase Guanosine 3â€²,5â€²-Monophosphate in LLC-PK1Kidney Epithelial Cells*. Endocrinology, 1988, 122, 1478-1485.	2.8	28
302	Biochemical Mechanisms Underlying Vascular Smooth Muscle Relaxation. Journal of Cardiovascular Pharmacology, 1988, 12, 115-118.	1.9	113
303	Effect of In Vivo Nitroglycerin Therapy on Endothelium-Dependent and Independent Vascular Relaxation and Cyclic GMP Accumulation in Rat Aorta. Journal of Cardiovascular Pharmacology, 1987, 10, 371-378.	1.9	125
304	Regulation of Guanylate Cyclase by Atrial Natriuretic Factor and the Role of Cyclic GMP in Vasodilation. American Journal of the Medical Sciences, 1987, 294, 139-143.	1.1	38
305	Effects of Glyceryl Trinitrate on Endothelium-Dependent and -Independent Relaxation and Cyclic GMP Levels in Rat Aorta and Human Coronary Artery. Journal of Cardiovascular Pharmacology, 1987, 10, 82-89.	1.9	89
306	Atrial Natriuretic Factors Stimulate Accumulation and Efflux of Cyclic GMP in C6?2B Rat Glioma and PC12 Rat Pheochromocytoma Cell Cultures. Journal of Neurochemistry, 1987, 48, 522-528.	3.9	60

#	Article	IF	Citations
307	The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. Archives of Biochemistry and Biophysics, 1986, 251, 709-714.	3.0	41
308	Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochemical Pharmacology, 1986, 35, 3525-3531.	4.4	149
309	Effects of atriopeptins on relaxation and cyclic GMP levels in human coronary artery in vitro. European Journal of Pharmacology, 1986, 124, 193-196.	3.5	32
310	Effects of atriopeptins on relaxation and cyclic GMP levels in rat and rabbit aortas. European Journal of Pharmacology, 1986, 120, 123-126.	3.5	30
311	Regulation of Cyclic GMP Synthesis and the Interactions with Calcium. Journal of Cardiovascular Pharmacology, 1986, 8, S57-S60.	1.9	13
312	Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. Biochimica Et Biophysica Acta - Molecular Cell Research, 1985, 846, 179-184.	4.1	99
313	Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta. European Journal of Pharmacology, 1985, 115, 219-229.	3.5	88
314	A common antigenic determinant found in two functionally unrelated toxins.. Journal of Experimental Medicine, 1984, 160, 1253-1258.	8.5	17
315	A Simple, Sensitive, and Specific Assay for the Heat-Stable Enterotoxin of Escherichia coli. Journal of Infectious Diseases, 1984, 149, 83-89.	4.0	34
316	Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7661-7664.	7.1	482
317	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase. Molecular and Cellular Biochemistry, 1983, 57, 155-166.	3.1	27
318	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase. Molecular and Cellular Biochemistry, 1983, 57, 155.	3.1	3